{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:27:09Z","timestamp":1761895629487},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Drug Investig."],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/bf03256922","type":"journal-article","created":{"date-parts":[[2013,3,3]],"date-time":"2013-03-03T01:35:12Z","timestamp":1362274512000},"page":"839-851","source":"Crossref","is-referenced-by-count":49,"title":["Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects"],"prefix":"10.1007","volume":"31","author":[{"given":"Stephan A.","family":"Veltkamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kadokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter J. J.","family":"Krauwinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald A.","family":"Smulders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,24]]},"reference":[{"key":"BF03256922_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.arcmed.2005.01.003","volume":"36","author":"J.L. Leahy","year":"2005","unstructured":"Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197\u2013209","journal-title":"Arch Med Res"},{"key":"BF03256922_CR2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/archinte.1994.00420210113013","volume":"154","author":"S.E. Moss","year":"1994","unstructured":"Moss SE, Klein R, Klein BE, et al. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994; 154: 2473\u20139","journal-title":"Arch Intern Med"},{"key":"BF03256922_CR3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/diacare.18.2.258","volume":"18","author":"R. Klein","year":"1995","unstructured":"Klein R. Hyperglycemia and microvascular and macro-vascular disease in diabetes. Diabetes Care 1995; 18: 258\u201368","journal-title":"Diabetes Care"},{"key":"BF03256922_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"D.M. Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, et al., American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193\u2013203","journal-title":"Diabetes Care"},{"key":"BF03256922_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","volume":"291","author":"S.H. Saydah","year":"2004","unstructured":"Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335\u201342","journal-title":"JAMA"},{"key":"BF03256922_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","volume":"95","author":"S. Nair","year":"2010","unstructured":"Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 34\u201342","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03256922_CR7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F. Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419\u201330","journal-title":"Lancet"},{"key":"BF03256922_CR8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","volume":"53","author":"O. Marsenic","year":"2009","unstructured":"Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875\u201383","journal-title":"Am J Kidney Dis"},{"key":"BF03256922_CR9","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"E.M. Wright","year":"2001","unstructured":"Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10\u20138","journal-title":"Am J Physiol Renal Physiol"},{"key":"BF03256922_CR10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","volume":"70","author":"J.J. Neumiller","year":"2010","unstructured":"Neumiller JJ, White Jr JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377\u201385","journal-title":"Drugs"},{"key":"BF03256922_CR11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","volume":"62","author":"S.A. Jabbour","year":"2008","unstructured":"Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279\u201384","journal-title":"Int J Clin Pract"},{"key":"BF03256922_CR12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V. Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22: 104\u201312","journal-title":"J Am Soc Nephrol"},{"key":"BF03256922_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/350354a0","volume":"350","author":"E. Turk","year":"1991","unstructured":"Turk E, Zabel B, Mundlos S, et al. Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter. Nature 1991; 350: 354\u20136","journal-title":"Nature"},{"key":"BF03256922_CR14","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","volume":"14","author":"R. Santer","year":"2003","unstructured":"Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14: 2873\u201382","journal-title":"J Am Soc Nephrol"},{"key":"BF03256922_CR15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","volume":"182","author":"S. Vestri","year":"2001","unstructured":"Vestri S, Okamoto MM, de Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182: 105\u201312","journal-title":"J Membr Biol"},{"key":"BF03256922_CR16","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H. Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427\u201334","journal-title":"Diabetes"},{"key":"BF03256922_CR17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","volume":"149","author":"H.S. Freitas","year":"2008","unstructured":"Freitas HS, Anh e GF, Melo KF, et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008; 149: 717\u20134","journal-title":"Endocrinology"},{"key":"BF03256922_CR18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"J.F. List","year":"2009","unstructured":"List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650\u20137","journal-title":"Diabetes Care"},{"key":"BF03256922_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11892-010-0095-5","volume":"10","author":"A.K. Patel","year":"2010","unstructured":"Patel AK, Fonseca V. Turning glucosuria into a therapy: efficacy and safety with SGLT2 inhibitors. Curr Diab Rep 2010; 10: 101\u20137","journal-title":"Curr Diab Rep"},{"key":"BF03256922_CR20","unstructured":"Kurosaki E, Tahara A, Yokono M, et al. In vitro and in vivo pharmacological properties of ASP1941, a novel, potent and selective SGLT2 inhibitor [abstract no. 0570-P]. American Diabetes Association, 70th Scientific Sessions; 2010 June 25\u201329; Orlando (FL)"},{"key":"BF03256922_CR21","unstructured":"Takasu T, Tahara A, Yokono M, et al. ASP1941, a novel, potent and selective SGLT2 inhibitor, improves hemoglobin A1c and symptoms of diabetes in animal models [abstract no. 0562-P]. American Diabetes Association, 70th Scientific Sessions; 2010 June 25\u201329; Orlando (FL)"},{"key":"BF03256922_CR22","unstructured":"Data on file. Internal Report 1941-ME-0040. Identification of ASP1941 metabolites in humans, 12 March 2010. Astellas Pharma Inc., Kashima, Osaka"},{"key":"BF03256922_CR23","unstructured":"Data on file. Internal Report 1941-PH-0029. Inhibitory activities of human metabolites of ASP1941 on cellular uptake of methyl-\u03b1-D-glucopyranoside (AMG) in human Na+-glucose cotransporter (SGLT)-expressing cells, 12 April 2010. Astellas Pharma Inc., Tsukuba, Ibaraki"},{"key":"BF03256922_CR24","unstructured":"Data on file. Internal report 1941-ME-0045. Correlation of ASP1941 metabolic activity with UGT enzyme activities in human liver microsomes, 29 March 2010. Astellas Pharma Inc., Kashima, Osaka"},{"key":"BF03256922_CR25","unstructured":"Data on file. Internal Report 1941-ME-0055. Inhibitory effects of ASP1941 on the activity of UDP-glucuronosyltransferases using human liver microsomes, 09 December 2010. XenoTech, LLC, Lenexa (KS)"},{"key":"BF03256922_CR26","unstructured":"Data on file. Internal Report 1941-ME-0039. Time-dependent inhibitory effects of ASP1941 on the activity of CYP isozymes using human liver microsomes, 16 October 2009. Sekisui Medical Co., Ltd, Muramatsu, Ibaraki"},{"key":"BF03256922_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cccn.2004.01.006","volume":"346","author":"C. Tassi","year":"2004","unstructured":"Tassi C, Mancuso F, Feligioni L, et al. Expression modes of urinary N-acetyl-beta-D-glucosaminidase in patients with chronic renal insufficiency. Clin Chim Acta 2004; 346: 129\u201333","journal-title":"Clin Chim Acta"},{"key":"BF03256922_CR28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000309421","volume":"29","author":"B. Lisowska-Myjak","year":"2010","unstructured":"Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 2010; 29: 357\u201365","journal-title":"Blood Purif"},{"key":"BF03256922_CR29","unstructured":"Data on file. Internal Report 1941-ME-0009. Validation of a LC-MS\/MS method for the determination of ASP1941 in human plasma, 04 December 2007. Astellas Pharma Europe B.V., Leiderdorp"},{"key":"BF03256922_CR30","unstructured":"Data on file. Internal Report 1941-ME-0010. Validation of a LC-MS\/MS method for the determination of ASP1941 in human urine, 04 December 2007. Astellas Pharma Europe B.V., Leiderdorp"},{"key":"BF03256922_CR31","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"C.J. Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223\u201333","journal-title":"Lancet"},{"key":"BF03256922_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00003081-199303000-00021","volume":"36","author":"J.D. Sobel","year":"1993","unstructured":"Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993; 36: 153\u201365","journal-title":"Clin Obstet Gynecol"},{"key":"BF03256922_CR33","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/diacare.23.12.1737","volume":"23","author":"S.E. Geerlings","year":"2000","unstructured":"Geerlings SE, Stolk RP, Camps MJ, et al., Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737\u201341","journal-title":"Diabetes Care"},{"issue":"5","key":"BF03256922_CR34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W. Meng","year":"2008","unstructured":"Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51(5): 1145\u20139","journal-title":"J Med Chem"},{"key":"BF03256922_CR35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B. Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520\u20136","journal-title":"Clin Pharmacol Ther"},{"key":"BF03256922_CR36","unstructured":"Schwartz S, Klasen S, Kowalski D, et al. ASP1941, a novel and selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), reduces fasting plasma glucose in patients with type 2 diabetes mellitus [abstract no. 0566-P]. American Diabetes Association, 70th Scientific Sessions; 2010 June 25\u201329; Orlando (FL)"},{"key":"BF03256922_CR37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B. Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513\u20139","journal-title":"Clin Pharmacol Ther"},{"key":"BF03256922_CR38","unstructured":"Kapur AR, O\u2019Connor-Semmes RL, Hussey EK, et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus [abstract no. 509-P]. American Diabetes Association, 69th Scientific Sessions; 2009 June 5\u20139; New Orleans (LA)"},{"key":"BF03256922_CR39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.smj.0000242866.81791.70","volume":"100","author":"P.J. Boyle","year":"2007","unstructured":"Boyle PJ, Zrebiec J. Physiological and behavioral aspects of glycemic control and hypoglycemia in diabetes. South Med J 2007; 100: 175\u201382","journal-title":"South Med J"},{"key":"BF03256922_CR40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1172\/JCI118803","volume":"98","author":"B.R. Landau","year":"1996","unstructured":"Landau BR, Wahren J, Chandramouli V, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996; 98: 378\u201385","journal-title":"J Clin Invest"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256922.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03256922\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T10:57:00Z","timestamp":1562756220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03256922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["BF03256922"],"URL":"https:\/\/doi.org\/10.1007\/bf03256922","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}